ArticleMolecular oncology2015

Preclinical evaluation of bortezomib/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies.

Ahmed E Goda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.